22.8 C
August 18, 2022

Biofarm registers a net profit of lei 60 million in 2021, up by 11% compared to 2020

  • Biofarm registers a turnover of lei 239 million in 2021, up by 10% compared to 2020
  • The net profit increased by 11%, to 60 million lei
  • EBITDA reached 82 million lei, an increase of 10% compared to 2020
  • In the CHC segment, Biofarm is second place in volume terms
  • Biofen Extra, the latest brand release from the Biofarm portfolio, becomes the value leader in the ibuprofen and paracetamol combination segment, within the first eight months of its launch


Biofarm, one of the most important drug manufacturers in Romania, reports positive developments for the preliminary results of 2021: turnover of 239 million lei and a net profit of 60 million lei, up 11% compared to 2020. In addition, Biofarm reported EBITDA of 82 million lei, up 10% compared to 2020.

“Innovation, the driving force behind Biofarm’s mission, is strongly reflected in the figures for 2021, a year marked by significant achievements in all areas. The main events that defined Biofarm in 2021 were: the celebration of 100 years of uninterrupted activity, the inauguration of one of the most modern drug factories in Romania and the launch of Biofen Extra, through which we activated one of the most important CHC categories in terms of business potential,” said Cătălin Vicol, General Manager of Biofarm.

 In terms of sell-out (sales from pharmacies to patients), Biofarm finished last year on the second position in terms of volume, respectively on the fourth position in terms of value in the category of CHC (Consumer Health Care). The launch of Biofen Extra consolidates Biofarm’s position in the top companies in the CHC category by activating one of the most important CHC categories in Romania – pain management. Biofen Extra, an OTC (Over-the-Counter) drug indicated in the treatment of severe pain, became a value leader in the ibuprofen and paracetamol combination segment within the first 8 months of its launch.

At the end of 2021, in the CHC category, Biofarm is the volume leader in the reference markets of nine brands in the portfolio: Colebil, Triferment, Bixtonim, Sennalax, Carmol, Nervocalmin, Carbocit, Extravalerianic and Devaricid.

Constant investments to increase brand capital, especially for the main brands in Biofarm’s portfolio, were also an important pillar in 2021. Over the past year, the process of revitalizing the visual identity for 9 other brands in Biofarm’s portfolio was completed. Consistent resources have also been allocated to launch new 360-degree communication campaigns to increase notoriety and test rate for portfolio-focused focus brands.

Biofarm’s portfolio covers the most important therapeutic areas in the Consumer Healthcare division – digestive & metabolic, respiratory & ORL, cardiovascular & circulatory, nervous system, multivitamins, with over 20 representative brands.

Biofarm continues to invest in the future and make a significant contribution to the long-term development of the Romanian pharmaceutical industry.


The state-of-the-art manufacturing equipment / systems in the new production facility allow continuous process monitoring, thus ensuring the production of high-quality medicines that meet the most stringent requirements of European legislation.


With a usable area of over 10,000 square meters and an annual production flow of over 30 million commercial units of tablets and capsules and more than 10 million liquid products, the new Biofarm plant is in line with the company’s strategic objectives: developing the portfolio through line extensions or new product launches and expanding to external markets.



Related posts

Cushman & Wakefield Equinox reveals that Bucharest has been the most dynamic logistics market in the region, becoming a regional hub


Romtelecom-Cosmote merger underway before BVB listing

Nine O' Clock